GRIN2B Knockdown in iSPNs for Levodopa-Induced Dyskinesia
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for levodopa-induced dyskinesia (LID) in Parkinson's disease either fail to effectively manage dyskinesias or introduce additional deficits, and surgical interventions like deep brain stimulation carry risks and variable effectiveness.
Innovation Solution
Administering a GRIN2B inhibitor to knock down the expression of the GluN2B subunit of N-methyl-d-aspartate receptors in indirect pathway spiny projection neurons (iSPNs) to attenuate the development and expression of LID, using nucleic acid inhibitors such as microRNA, siRNA, or shRNA delivered via viral vectors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If higher oral doses of levodopa are required to achieve symptomatic benefit in later stages of PD, then motor symptoms are better controlled, but brain concentrations of DA become dysregulated and LID develops
Solution Approach 1:
The patent extracts and targets the specific harmful mechanism (GluN2B subunit in indirect pathway SPNs) that mediates LID, while preserving the beneficial effect of levodopa. By selectively knocking down GRIN2B expression in indirect pathway SPNs, the harmful dyskinesic effects are removed without interfering with the dopaminergic therapy's motor control benefits.
Solution Approach 2:
The patent applies local quality by targeting GRIN2B specifically in indirect pathway spiny projection neurons rather than globally. This selective localization allows the treatment to address LID in the specific neuronal population where GluN2B is pathologically upregulated, while leaving direct pathway neurons and other brain regions unaffected, thus preserving levodopa efficacy.
2Object-affected harmful factors
If adjusting levodopa dosage or introducing new medications to manage LID, then dyskinesias are reduced, but motor control fluctuations and side effects increase
Solution Approach 1:
The patent introduces GRIN2B knockdown as an intermediary mechanism that mediates between levodopa administration and LID expression. By targeting the glutamatergic signaling pathway (specifically NMDA receptors with GluN2B subunits) in indirect pathway SPNs, the treatment acts as a bridge that prevents LID without interfering with dopaminergic signaling, thus maintaining motor control stability.
3Object-affected harmful factors
If deep brain stimulation is used to treat LID, then motor complications are managed, but surgical risks and variable effectiveness occur
Solution Approach 1:
The patent replaces the mechanical/surgical intervention (deep brain stimulation) with a molecular/biological approach (GRIN2B knockdown via nucleic acid inhibitors). This substitution eliminates surgical risks such as infection, bleeding, and stroke, while providing a non-invasive treatment that can be administered systemically, thereby improving accessibility and reducing variability in treatment outcomes.
Data Source
AI summary
The present disclosure provides compositions and methods for the treatment of levodopa-induced dyskinesia (LID) therewith. In particular, the present disclosure provides methods for treating LID by knocking down expression of the gene (GRIN2B) coding for the GluN2B subunit of N-methyl-d-aspartate receptors in indirect pathway spiny projection neurons (iSPNs) to attenuate the development and expression of LID without compromising the treatment of levodopa.